Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
Mauro Rosales, George Perez, Ailyn C. Ramòn, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 766-766
Open Access | Times Cited: 17

Showing 17 citing articles:

Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment
Konjeti R. Sekhar, Michael L. Freeman
Cancer Research (2023) Vol. 83, Iss. 10, pp. 1573-1580
Open Access | Times Cited: 16
CK2: the master regulator in tumor immune-microenvironment - a crucial target in oncotherapy
Subhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.
European Journal of Pharmacology (2025), pp. 177376-177376
Closed Access
Time- and dose-dependent effects of CIGB-300 on the proteome of lung squamous cell carcinoma
Liudy García Hernández, Dai L, Arielis Rodríguez‐Ulloa, et al.
Biological Chemistry (2025)
Closed Access
The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer
Huixian Hong, Etty Benveniste
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1932-1932
Open Access | Times Cited: 23
In Vitro Kinase-to-Phosphosite Database (iKiP-DB) Predicts Kinase Activity in Phosphoproteomic Datasets
Tommaso Mari, Kirstin Mösbauer, Emanuel Wyler, et al.
Journal of Proteome Research (2022) Vol. 21, Iss. 6, pp. 1575-1587
Open Access | Times Cited: 15
Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms
Emanuela Pucko, Robert P. Ostrowski
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 331-331
Open Access | Times Cited: 9
Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
Ailyn C. Ramòn, George Perez, Evelín Caballero, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 552-552
Open Access | Times Cited: 9
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
George Perez, Mauro Rosales, Ailyn C. Ramòn, et al.
Biomedicines (2022) Vol. 11, Iss. 1, pp. 43-43
Open Access | Times Cited: 9
Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
Dania Vázquez‐Blomquist, Ailyn C. Ramòn, Mauro Rosales, et al.
BMC Genomics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 4
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
Ailyn C. Ramòn, Om Basukala, Paola Massimi, et al.
Viruses (2022) Vol. 14, Iss. 8, pp. 1681-1681
Open Access | Times Cited: 7
Anticancer Tetrahydrocarbazoles: A Wide Journey from 2000 Till Date
Nitin Kumar, Pankaj Gupta
Letters in Drug Design & Discovery (2022) Vol. 21, Iss. 3, pp. 421-439
Closed Access | Times Cited: 6
CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition
Mauro Rosales, Arielis Rodríguez‐Ulloa, George Perez, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 5
“Phosphoproteomic quantification based on phosphopeptide intensity or occupancy? An evaluation based on casein kinase 2 downstream effects”
Arielis Rodríguez‐Ulloa, Mauro Rosales, Yassel Ramos, et al.
Journal of Proteomics (2024) Vol. 307, pp. 105269-105269
Closed Access
Towards the CSNK2 phosphoproteome – With lessons from the COVID-19 pandemic to revealing the secrets of CSNK2 and its promise as a therapeutic target
David W. Litchfield, Laszlo Gyenis, Daniel Menyhart, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2023) Vol. 1867, Iss. 10, pp. 130441-130441
Closed Access | Times Cited: 1
CIGB-300 peptide targets the CK2 phospho-acceptor domain on Human Papillomavirus E7 and disrupts the Retinoblastoma (RB) complex in cervical cancer cells
Ailyn C. Ramòn, Om Basukala, Paola Massimi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells
Dania Vázquez‐Blomquist, Ailyn C. Ramòn, Mauro Rosales, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
On Casein Kinase-2 (CK2) deregulation in NSCLC: an enzyme subunit-centered approach
George Perez, Li Chen, Deng Chenyi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
In vitro Kinase-to-Phosphosite database (iKiP-DB) predicts kinase activity in phosphoproteomic datasets
Tommaso Mari, Kirstin Mösbauer, Emanuel Wyler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top